-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the NMPA official website released the latest batch of drug approval information, and another company passed the consistency evaluation of omeprazole sodium for injection.
Figure 1: The latest review of enterprises with Omeprazole Sodium for Injection
Source: NMPA official website
Omeprazole is the world's first approved proton pump inhibitor.
Figure 2: The share of TOP5 companies in Omeprazole Sodium for Injection in 2020
Source: Mi Nei.
In 2020, in China's public medical institutions, Osaikon will occupy more than 40% of the market share of Omeprazole Sodium for injection.
As of now, in addition to Omeprazole Sodium for injection, the companies that have reviewed omeprazole sodium include Shandong Luoxin Pharmaceutical, Shandong New Times Pharmaceutical, Guangzhou Poinsettia Pharmaceutical, Hainan Beite Pharmaceutical, Hunan Kelun Pharmaceutical, and Hunan Saican.
Table 1: Sales and national procurement of PPI injections
Source: Mi Nei.
At present, among the best-selling PPI injections in public medical institutions in China, pantoprazole, esomeprazole (esomeprazole) and lansoprazole have been included in the national procurement, and there are no companies for rabeprazole injections.
Source: NMPA official website, Mi Nei.